Your insurance denied Ozempic, Wegovy, or Mounjaro? The denial is usually about paperwork — not you.
GLP-1 weight-loss drugs are among the most tightly managed prescriptions in the country — plans stack prior authorization, step therapy, BMI and comorbidity criteria, and outright weight-loss exclusions on top of one another. Out of pocket, these medications often run well over $1,000 a month, so a denial can put treatment out of reach overnight. Most denials turn on prior-authorization rules, step therapy, plan exclusions, and clinical documentation.
Upload your denial letter. Lysco identifies the exact reason, maps the step-therapy and exception arguments that fit it, and drafts an appeal with clinical citations. Your first read is free.
Free to see exactly what’s wrong. $9 to unlock the full appeal — only if you choose to proceed. No subscription. No credit card to start.
Your appeal has a real deadline — and the clock is already running.
Most commercial and ACA marketplace plans give you at least 180 days from the denial notice to file an internal appeal. Medicare Part D drug appeals can be as short as 60 days, and some Medicaid timelines are shorter still. The clock starts from the date on the letter — check yours now.
Check my deadline — free first readThe numbers
<1%
Of denied ACA Marketplace in-network claims were formally appealed
KFF, 2024 data
~1 in 3
Of internal appeals that WERE filed ended with the denial overturned
KFF, 2024 data
$50
Copay for eligible Part D beneficiaries under the short-term Medicare GLP-1 Bridge, running now through Dec 31, 2027
CMS, 2026
These are aggregate U.S. denial-appeal statistics across all categories — they describe a population, not a prediction for your case. GLP-1 outcomes specifically depend on your plan’s step-therapy rules, BMI/comorbidity criteria, and the clinical documentation your prescriber provides.
Drugs we handle
Lysco handles denials for every major GLP-1
Ozempic
Type 2 diabetes
Mounjaro
Type 2 diabetes
Rybelsus
Type 2 diabetes (oral)
Saxenda
Weight management
Trulicity
Type 2 diabetes
Victoza
Type 2 diabetes
Other GLP-1s
Any brand or generic
Denial playbook
Why insurers deny GLP-1s — and what works in appeal
Step therapy not completed
Insurers often require you to “fail” cheaper drugs (metformin, phentermine) first. If you’ve documented intolerance, contraindication, or prior failure, that waives the requirement. Upload those records and Lysco builds the argument from them.
BMI or comorbidity threshold not met
BMI ≥30, or ≥27 with at least one weight-related condition, are common FDA-labeled adult indications for chronic weight-management drugs such as Wegovy and Zepbound — not a universal plan coverage standard. Compare the denial with the drug label and your plan’s actual criteria.
Weight-loss use not covered
Many plans exclude weight-management indications but cover Type 2 diabetes. If you have related conditions, we cite ADA and endocrinology guidelines for broader medical necessity.
Prior authorization required
Many GLP-1 denials are PA failures, step-therapy issues, or plan-exclusion questions rather than a pure medical rejection. We build the PA with the documentation the insurer needs.
Plan formulary exclusion
If the specific drug isn’t on formulary but a similar GLP-1 is, we request a formulary exception with clinical justification for why your prescriber chose this one.
Quantity or dose limits
If your prescriber escalated your dose per the approved titration schedule, the denial is often procedurally wrong. We cite the FDA-approved titration.
What changed
Why 2026 is different
Medicare is testing a limited bridge. The Medicare GLP-1 Bridge is a short-term CMS demonstration that began July 1, 2026 and runs through December 31, 2027. Eligible Medicare Part D beneficiaries pay a $50 copay for certain GLP-1 drugs. You have to be 18 or older and meet a BMI threshold (35 or higher, or lower with specific conditions), your provider has to complete a prior authorization and confirm you are also following a diet-and-exercise program, and you are not eligible if your own Part D plan already covers your GLP-1. The demonstration sits outside the Part D benefit’s normal coverage and payment flow — the deductible does not apply, the copay does not count toward your out-of-pocket total, and it is not blanket Medicare coverage. Check the current rules at medicare.gov/glp1bridge.
State Medicaid is contracting. Pennsylvania, California, New Hampshire, and South Carolina have cut or limited GLP-1 coverage in 2026. If you’re on Medicaid and lost coverage, an appeal — or a shift to a covered indication — may still work.
Commercial plans are tightening. From 2025 to 2026, roughly 12 million people were on plans that dropped Wegovy coverage, and about 12 million were on plans that dropped Zepbound (GoodRx research). More than 90% of commercial plans now require prior authorization for GLP-1 weight-loss drugs. The stronger your documentation, the higher your odds. Lysco builds that documentation into every appeal.
Formulary swaps are triggering denials of their own. In 2025 CVS Caremark removed Zepbound from its main commercial formulary and made Wegovy the preferred obesity GLP-1 — a switch it is reversing effective October 1, 2026, when Zepbound returns as a co-preferred option. If a formulary change like this forced you off a drug that was working, a formulary-exception request with clinical justification is often the right appeal path. See the CVS Caremark / Zepbound guide.
The process
How Lysco appeals a GLP-1 denial
Upload the denial or PA rejection
Photo, PDF, or paste the text. We read it in seconds and extract the specific reason.
We identify the fix
Step therapy? BMI threshold? Formulary exclusion? We match the denial to the right appeal argument.
We draft the appeal with clinical citations
ADA guidelines, endocrinology society statements, FDA-approved titration schedules, and your plan’s own policy language.
You review, sign, and send
Or give it to your prescriber to co-sign. We include the exact submission address and deadline.
Your exact situation
Go deeper on your specific denial
Questions
GLP-1 appeal questions, answered straight
How much does it cost?
Your first read is free — upload the denial and see exactly what went wrong and what your appeal options are. If you decide to proceed, it is a flat $9 to unlock the full ready-to-sign appeal and submission instructions. No subscription, no recovery fee, no credit card to start.
Is my denial letter private?
Yes. Documents are encrypted in transit and at rest, access to them is controlled, and you can delete your documents and account at any time.
My denial says weight-loss drugs aren’t covered. Is an appeal still possible?
Sometimes. A plan-design exclusion is harder to beat than a medical-necessity denial, but appeals can still turn on a covered indication (for example Type 2 diabetes, or the cardiovascular and sleep-apnea indications on some GLP-1 labels), a formulary-exception right, or documentation the plan never reviewed. The free first read tells you honestly which situation yours is — including when the case is weak.
How long do I have to appeal?
Most commercial and ACA marketplace plans give you at least 180 days from the denial notice for an internal appeal. Medicare Part D drug appeals can be as short as 60 days, and some Medicaid timelines are shorter. The date on your denial letter starts the clock — check it now.
Do I need my doctor to appeal?
No — you can file the appeal yourself. But prescriber documentation (prior treatments tried, intolerance, clinical rationale) makes appeals materially stronger, and Lysco marks exactly where a prescriber letter or co-signature would help.
Does Lysco submit the appeal for me?
No. Lysco prepares the appeal with the exact submission address and your deadline; you review, sign, and send it yourself. Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate, and it never contacts your insurer on your behalf.
Start your GLP-1 appeal — free
Your first read is free. 30 seconds to upload. No credit card needed.
Appeal my GLP-1 denialEncrypted in transit and at rest · Access controlled · Delete anytime
Lysco is an informational tool — not a law firm, medical provider, or licensed patient advocate. We don’t prescribe or recommend medications. GLP-1 prescribing is a decision for you and your doctor. Appeal outcomes vary by plan, diagnosis, documentation, and circumstances. This page is not medical or legal advice. Ozempic, Wegovy, Mounjaro, and Zepbound are trademarks of their respective manufacturers.